Some price data may be temporarily unavailable.
The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.
The biotech delivers some highly encouraging news on the clinical front.
The biotech's Q2 financial results are concerning investors today.
CLVS earnings call for the period ending March 31, 2020.
CLVS earnings call for the period ending December 31, 2019.
CLVS earnings call for the period ending September 30, 2019.
CLVS earnings call for the period ending June 30, 2019.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.